Featured Research

from universities, journals, and other organizations

Drug Study For Brain Cancer Shows Promising Results

Date:
December 14, 2007
Source:
Henry Ford Health System
Summary:
A clinical study on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

Related Articles


The randomized Phase II study focused on patients with glioblastoma multiforme (GBM), whose cancer had recurred after first- or second-line therapy. The study revealed that more than a third who were treated with Avastin (bevacizumab) alone, as well as more than half of those treated with Avastin in combination with the chemotherapy drug irinotecan, lived without further progression of the disease for a period of six months. In addition, no new or unexpected adverse effects from the use of Avastin were observed during the study.

"This is very encouraging news," says Tom Mikkelsen, M.D., a neuro-oncologist who is the study's principal investigator at Henry Ford and co-director of the Hermelin Brain Tumor Center. "Historical estimates suggest that only 15 percent of patients with this aggressive type of brain cancer live without their cancer progressing within six months. Although gliomas [fast-growing malignant brain tumors] are nearly always incurable, use of a drug like Avastin may help to buy precious time for patients, as well as to preserve their physical and mental functions longer than was previously possible."

Avastin is a therapeutic antibody designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that stimulates development of new blood vessels in a process known as angiogenesis, while maintaining existing tumor vessels. By binding to VEGF, Avastin acts as an anti-angiogenesis agent that chokes off the blood supply to tumors, which in turn inhibits their growth and metastasis.

The national study is sponsored by Genentech and Henry Ford Hospital is one of the large study sites.

"The same process that makes gliomas so deadly may turn out to be exactly the same thing that makes it possible to slow down their progression," Dr. Mikkelsen says. "This is a very significant advance in the battle to control these aggressive tumors because it could lead to treatment options where none existed previously for patients with recurrent disease."

Previously Avastin had been used in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer and lung cancer. Because of its demonstrated success rate with these cancers, Avastin currently is being studied worldwide in more than 300 clinical trials for 20 different tumor types.

"With currently approved therapies, the chances of suppressing GBM are poor at less than 10 percent," says Dr. Mikkelsen. "This type of targeted therapy using Avastin may prove to be the best new hope we have for helping patients with recurrent disease who previously had few options available to them."

According to the American Cancer Society (ACS), the five-year survival rate for patients with GBM is 3 percent, a figure that has not changed in more than 25 years. The ACS estimates there will be 20,500 new cases of brain cancer and 12,740 brain cancer deaths in 2007.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Drug Study For Brain Cancer Shows Promising Results." ScienceDaily. ScienceDaily, 14 December 2007. <www.sciencedaily.com/releases/2007/12/071213120952.htm>.
Henry Ford Health System. (2007, December 14). Drug Study For Brain Cancer Shows Promising Results. ScienceDaily. Retrieved November 21, 2014 from www.sciencedaily.com/releases/2007/12/071213120952.htm
Henry Ford Health System. "Drug Study For Brain Cancer Shows Promising Results." ScienceDaily. www.sciencedaily.com/releases/2007/12/071213120952.htm (accessed November 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com
Ebola: Life Without School in Guinea

Ebola: Life Without School in Guinea

AFP (Nov. 21, 2014) Following the closure of schools and universities in Guinea because of the Ebola virus, students look for temporary work or gather in makeshift classrooms to catch up on their syllabus. Duration: 02:14 Video provided by AFP
Powered by NewsLook.com
UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins